Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving the request. Pancreatic cancer is among the most lethal cancers in existence, with a five-year survival rate of only about 3 percent for the most common metastatic form, and until now new treatment options have been frustratingly scarce for patients who have already tried conventional therapies. The speed of the FDA’s response was itself notable: the regulator received Revolution Medicines’ expanded access application on April 28th and signed it on April 30th, and the FDA Commissioner said the two-day turnaround reflects the agency’s commitment to getting promising treatments to patients with life-threatening conditions without delay. The pill works by targeting a protein called RAS, which is mutated in the majority of pancreatic cancer tumors and had for decades been considered essentially undruggable.

In a closely watched phase 3 trial called RASolute 302, daraxonrasib produced results the oncology community called unprecedented: patients taking the pill survived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death. The drug is taken orally once a day and was generally well tolerated in the trial, with no new safety signals reported. Daraxonrasib has also received Breakthrough Therapy and Orphan Drug designations from the FDA, and the company says it intends to submit a full new drug application under the FDA’s national priority program. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access to the drug for eligible patients across the United States.

Source: https://www.reuters.com/legal/litigation/us-fda-authorizes-early-access-revolutions-pancreatic-cancer-pill-2026-05-01/

PrevPreviousCommunities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78
NextA Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New HomeNext

Recent Articles

Happy News

For The First Time In History Medicare Is Covering Weight Loss Drugs And The Price Is $50 A Month

May 14, 2026

Starting July 1, 2026 eligible Medicare enrollees will be able to access GLP-1 weight loss medications including Wegovy, Zepbound, and the newer drug Foundayo for a flat $50 monthly copay, in a historic first for the program, which has never before covered anti-obesity medications despite covering many of the serious

Read More
Happy News

Swedish Scientists Just Grew The Cells Type 1 Diabetes Destroys From Scratch

May 13, 2026

Scientists at Karolinska Institutet and KTH Royal Institute of Technology in Sweden have developed a more reliable method for growing insulin-producing cells from human stem cells, and the results published in Stem Cell Reports represent one of the most encouraging steps yet toward a potential treatment for type 1 diabetes.

Read More
Happy News

New Research Reveals The Personality Trait That Predicts Whether You Will Seek Out A Cat When Stressed

May 12, 2026

A study published in the journal Anthrozoös, conducted by researchers at Washington State University and KU Leuven in Belgium, has identified the personality trait most likely to predict whether someone will seek out a cat for stress relief rather than a dog, and the answer has a name: emotionality. Researchers

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.